NR1H4 and metabolic dysfunction-associated steatotic liver disease: Recent investigations have highlighted the significance of FXR as a critical therapeutic target in NAFLD, with encouraging findings showcasing the substantial amelioration of pathological manifestations in patients with NASH upon treatment with FXR agonists [53].